Cupid posts 133% Q2 profit jump, lifts FY27 guidance; shares hit 52‑week high
Cupid Ltd reported a 133% YoY rise in Q2 FY27 net profit to ₹56.22 cr, raised FY27‑FY29 targets and saw its stock climb 10% to a 52‑week high of ₹389.
Key Takeaways
- Q2 FY27 net profit rose 133% YoY to ₹56.22 cr, while revenue grew 122% to ₹187.86 cr.
- Management raised FY27 revenue guidance to ≥₹880 cr and net profit to ≥₹275 cr, with FY28‑FY29 targets of ₹1,305 cr/₹390 cr and ₹1,950 cr/₹605 cr respectively.
- New exclusive retail tie‑ups with V2 Retail and Style Baazar aim to add ₹200 cr in FY27 sales, scaling to >₹500 cr over the next few years.
Cupid Ltd announced on 12 Nov 2026 that its Q2 FY27 consolidated net profit more than doubled to ₹56.22 crore, a 133% year‑on‑year increase, and revenue climbed 122% to ₹187.86 crore. The results propelled the stock 10% higher to a 52‑week high of ₹389 on the BSE, underscoring the impact of its expanding domestic consumer‑healthcare and FMCG franchise.
What Happened
- Q2 FY27 performance: Net profit ₹56.22 cr (+133% YoY) and revenue ₹187.86 cr (+122% YoY). EBITDA stood at ₹54.77 cr, delivering a 29% operating margin.
- H1 FY27 snapshot: Net profit ₹100.37 cr (+156% YoY), revenue ₹342.58 cr (+137% YoY), EBITDA ₹114.83 cr (+156% YoY).
- Domestic consumer segment: Contributed ₹224.64 cr (67% of H1 sales), with the Consumer Healthcare & FMCG sub‑segment accounting for ₹166.88 cr (49% of total).
- Retail partnerships: Exclusive long‑term agreement with V2 Retail (signed 4 Nov 2026) and expanded placement in >290 Style Baazar stores, projected to generate ₹200 cr in FY27 and >₹500 cr thereafter.
- Guidance uplift: FY27 revenue target raised to at least ₹880 cr (previously ₹600 cr) and net profit to ≥₹275 cr (previously ₹180 cr). FY28 and FY29 targets also lifted to ₹1,305 cr/₹390 cr and ₹1,950 cr/₹605 cr respectively.
Financial Analysis & Context
| Metric | Q2 FY26 | Q2 FY27 | YoY % | H1 FY26 | H1 FY27 | YoY % |
|---|---|---|---|---|---|---|
| Revenue (₹ cr) | 86.13 | 187.86 | +122% | 155.23 | 342.58 | +121% |
| Net Profit (₹ cr) | 24.13 | 56.22 | +133% | 39.14 | 100.37 | +156% |
| EBITDA (₹ cr) | 21.09 | 54.77 | +160% | 44.32 | 114.83 | +159% |
| Operating Margin | 24.5% | 29.0% | — | 28.6% | 33.5% | — |
One‑off items: No exceptional items were disclosed; the performance reflects core operating growth.
Independent Analysis & Key Risks
Strategic significance: The sharp profit acceleration is driven by a shift toward higher‑margin consumer healthcare products and a rapid rollout in organised retail, which should improve pricing power and distribution efficiency.
Execution risk: Scaling retail presence depends on supply‑chain reliability and the ability to sustain price revisions in export markets. Any disruption in raw‑material sourcing or a slowdown in retail partner roll‑out could blunt margin expansion.
Competitive landscape: Larger FMCG players are also expanding health‑care lines; Cupid must protect its niche through product differentiation and continued cost‑efficiency gains.
Financial risk: The ambitious FY28‑FY29 targets assume continued double‑digit revenue growth and margin improvement. A slowdown in domestic demand or adverse foreign‑exchange movements could impair the outlook.
Disclaimer: This report is for informational purposes only and does not constitute investment advice.
Sources & References
- View sourceLivemintNews Report
Multibagger stock: Cupid shares jump 10% as profit soars 133% in Q2 results 2026; already up 262% in 2026 — What's next?
- View sourceBusiness StandardNews Report
Cupid Share Price: Cupid shares jump 10% to record high on 133% Q2 PAT growth, higher guidance
- View sourceThe Economic TimesNews Report
Cupid shares hit fresh 52-week high as firm raises FY27 revenue, profit guidance again; multibagger stock
- View sourceThe Economic TimesNews Report
Cupid shares jump nearly 9% in two days post Q1 earnings
TradeKaizen Markets Desk
Equities & Market Coverage Desk
The TradeKaizen Markets Desk covers Indian equities, index movements, institutional flows, and exchange disclosures from NSE and BSE.